Complex/variant translocations in chronic myelogenous leukemia (CML): genesis and prognosis with 4 new cases

被引:1
作者
Mendiola, Christina [1 ]
Ortega, Veronica [1 ]
Tonk, Vijay S. [2 ]
Coviello, Jean M. [3 ]
Velagaleti, Gopalrao [1 ]
机构
[1] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA
[2] Texas Tech Univ, Dept Pediat, Lubbock, TX 79409 USA
[3] San Antonio Mil Med Ctr, Dept Pathol, San Antonio, TX USA
关键词
BCR/ABL; Variant translocation; CML; D-FISH; Complex rearrangement; CHRONIC MYELOID-LEUKEMIA; VARIANT TRANSLOCATIONS; CHROMOSOMES; EVOLUTION; PH1;
D O I
10.1016/j.yexmp.2014.06.004
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
In 5-10% of cases with CML, variant or complex translocations (CT) are seen that may result in atypical fluorescence in situ hybridization signal patterns. Dual color, dual fusion fluorescence in situ hybridization (D-FISH) patterns are instrumental in identifying the genesis of these CT, but their prognostic implications remain controversial. The most common mechanism is a two-step process in which a standard two-way translocation (9;22) is followed by subsequent rearrangements involving other chromosomes. The second common mechanism is the one-step process wherein breakage occurs simultaneously on different chromosomes leading to CT. The typical D-FISH pattern seen with the one-step mechanism is 1F2G2R, while the pattern for the two-step mechanism can be variable (2F1G1R, 1F1G1R, 1F1G2R, 1F2G1R, etc.). We have studied 4 cases of CT using metaphase FISH with triple color, dual fusion ASS1, ABL1 and BCR probes to understand the genesis of these CT. All the patients were treated with imatinib, but only patients 3 and 4 showed remission. Our results indicate that the CT in cases 1,3 and 4 arose from a one-step mechanism and case 2 from a multi-step mechanism. Response to imatinib varied from full remission to no response. Long term follow-up is necessary to evaluate the prognostic implications of these CT. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:105 / 110
页数:6
相关论文
共 50 条
[41]   The new genetics of chronic neutrophilic leukemia and atypical CML: implications for diagnosis and treatment [J].
Gotlib, Jason ;
Maxson, Julia E. ;
George, Tracy I. ;
Tyner, Jeffrey W. .
BLOOD, 2013, 122 (10) :1707-1711
[42]   New insights in cellular and molecular aspects of BM niche in chronic myelogenous leukemia [J].
Shahrabi, Saeid ;
Azizidoost, Shirin ;
Shahjahani, Mohammad ;
Rahim, Fakher ;
Ahmadzadeh, Ahmad ;
Saki, Najmaldin .
TUMOR BIOLOGY, 2014, 35 (11) :10627-10633
[43]   NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib [J].
Sopper, S. ;
Mustjoki, S. ;
Gjertsen, B. T. ;
Giles, F. ;
Hochhaus, A. ;
Janssen, J. J. W. M. ;
Porkka, K. ;
Wolf, D. .
LEUKEMIA, 2017, 31 (10) :2264-2267
[44]   Four Cases of Chronic Myelogenous Leukemia in Mixed Phenotype Blast Phase at Initial Presentation Mimicking Mixed Phenotype Acute Leukemia with t(9;22) [J].
Choi, Woojin ;
Kim, Myungshin ;
Lim, Jihyang ;
Han, Kyungja ;
Lee, Seok ;
Lee, Jae Wook ;
Chung, Nack Gyun ;
Kim, Yonggoo .
ANNALS OF LABORATORY MEDICINE, 2014, 34 (01) :60-63
[45]   Sequential transient novel chromosomal translocations in a patient with chronic myelogenous leukemia in complete cytogenetic remission after therapy with imatinib mesylate [J].
Papaioannou, George ;
Athanasiadou, Anastasia ;
Voutiadou, Georgia ;
Gaitatzi, Maria ;
Batsis, Ioannis ;
Touloumenidou, Tasoula ;
Anagnostopoulos, Achilles .
CANCER GENETICS, 2011, 204 (12) :692-693
[46]   Chronic Myelogenous Leukemia with the e6a2 BCR-ABL and Lacking Imatinib Response: Presentation of Two Cases [J].
Vefring, Hege K. ;
Gruber, Franz X. E. ;
Wee, Line ;
Hovland, Randi ;
Hjorth-Hansen, Henrik ;
Dahl, Tobias Gedde ;
Meyer, Peter .
ACTA HAEMATOLOGICA, 2009, 122 (01) :11-16
[47]   Measuring prognosis in chronic myeloid leukemia: what's new? [J].
Breccia, Massimo ;
Efficace, Fabio ;
Scalzulli, Emilia ;
Ciotti, Giulia ;
Maestrini, Giacomo ;
Colafigli, Gioia ;
Martelli, Maurizio .
EXPERT REVIEW OF HEMATOLOGY, 2021, 14 (06) :577-585
[48]   Tyrosine kinase inhibitors (TKI): a new revolution in the treatment of chronic myeloid leukemia (CML) [J].
Aviles-Vazquez, Socrates ;
Chavez-Gonzalez, Antonieta ;
Mayani, Hector .
GACETA MEDICA DE MEXICO, 2013, 149 (06) :646-654
[49]   Advances in treatment of chronic myelogenous leukemia - new treatment options with tyrosine kinase inhibitors [J].
Santos, Fabio P. S. ;
Ravandi, Farhad .
LEUKEMIA & LYMPHOMA, 2009, 50 (02) :16-26
[50]   INTERFERON ALFA-2C IN CHRONIC MYELOGENOUS LEUKEMIA (CML) - HEMATOLOGIC, CYTOGENETIC AND MOLECULAR-GENETIC RESPONSE OF PATIENTS WITH CHRONIC PHASE CML PREVIOUSLY RESISTANT TO THERAPY WITH INTERFERON-GAMMA [J].
HERRMANN, F ;
JONAS, D ;
HELFRICH, SG ;
LINDEMANN, A ;
SCHLEIERMACHER, E ;
MERTELSMANN, R .
BLUT, 1990, 61 (04) :226-231